Nucleic Acid Isolation and Purification Market World's Top Players are QIAGEN Inc., Thermo Fisher Scientific., F. Hoffmann-La Roche Ltd, Merck KGaA,, Agilent Technologies Inc., Illumina, Inc., Takara Bio Inc., Promega Corporation, General Electric Company

Increasing demand for nucleic acid test that is required for pipeline studies of genetic engineering and molecular diagnostics is the key driver for nucleic acid isolation and purification market growth. For Instance, in September 2012, GlaxoSmithKline initiated Phase 1 clinical study to evaluate the effects of chemotherapy and adoptive immunotherapy with T cells engineered to recognize NY-ESO-1 peptide in patients with unresectable, metastatic or recurrent synovial sarcoma. T immune cells are genetically engineered to express tumor-specific T cell receptor (TCR) genes and thereby kill cancer cells. The study is expected to complete by May 2020.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2420

High quality DNA and RNA are important for a wide variety of research and clinical applications. Purification or isolation of nucleic acids is the first step in most molecular biological studies and in all recombinant DNA techniques. The extraction of nucleic acids from biological material requires cell lysis, inactivation of cellular nucleases, and separation of the desired nucleic acid from cellular debris. Methods for purifying nucleic acids from cell extracts are often combinations of extraction/precipitation, chromatography, centrifugation, electrophoresis, and affinity separation. Pure nucleic acid has applications in emerging fields such as genetic engineering, molecular diagnosis, forensics, and research related to life sciences.

Furthermore, key players in Europe are focused on adopting acquisition strategies in order to enhance their market share. This in turn is expected to boost growth of the nucleic acid isolation and purification market in the region. For Instance, in February 2017, Qiagen Inc. acquired OmicSoft Corp. OmicSoft is recognized for its suite of software solutions that enable researchers to analyze and visualize their own datasets and compare them to massive volumes of publicly available ‘omics’ datasets. This acquisition aims at adding feature to the management, analysis, and sharing of both primary data and analyzed results, while also expanding the range of Qiagen’s translational and clinical applications.

Key players operating in the nucleic acid isolation and purification market include QIAGEN Inc., Thermo Fisher Scientific., F. Hoffmann-La Roche Ltd, Merck KGaA,, Agilent Technologies Inc., Illumina, Inc., Takara Bio Inc., Promega Corporation, General Electric Company, Danaher Corporation, New England Biolabs, and Bio-Rad Laboratories.

Request a Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/2420

Nucleic Acid Isolation and Purification Market - Taxonomy

By Product Type

DNA & RNA Extraction and Purification Kits
Reagents
Instruments
By Method:

Column-based Isolation and Purification
Reagent-based Isolation and Purification
Magnetic Bead-based Isolation and Purification
Others
By Type:

DNA Isolation and Purification
Genomic DNA Isolation & Purification
Plasmid DNA Isolation & Purification
Viral DNA isolation & Purification
Others
RNA Isolation & Purification
MiRNA Isolation and Purification
mRNA Isolation & Purification
Total RNA Isolation & Purification
Others
By Application:

Diagnostics
Precision Medicine
Drug Discovery and Development
Other Applications
By End User:

Pharmaceutical and Biotech Companies
Hospitals and Diagnostics Laboratories
Research Centers
Contract Research Organizations
By Region

North America
Europe
Asia Pacific
Latin America
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.